SoFi CEO enters prepaid forward contract on 1.5 million shares
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $660 billion and impressive revenue growth of 37% in the last twelve months, announced Wednesday that its breast cancer drug Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival when combined with endocrine therapy for patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. According to InvestingPro data, the company maintains a strong financial health score, reflecting its robust position in the pharmaceutical sector.
The positive results came from the primary overall survival analysis of the Phase 3 monarchE trial, which evaluated two years of Verzenio plus endocrine therapy compared to endocrine therapy alone. The seven-year landmark analysis also showed sustained benefits in invasive disease-free survival and distant relapse-free survival. With an industry-leading gross profit margin of 83% and 14 analysts recently revising their earnings estimates upward, Eli Lilly continues to demonstrate strong commercial execution. For deeper insights into Eli Lilly’s financial metrics and growth potential, InvestingPro subscribers have access to over 30 additional key metrics and exclusive analysis.
"These data validate Verzenio as the standard-of-care for patients with node-positive, high-risk disease," said Jacob Van Naarden, executive vice president and president of Lilly Oncology, in a statement based on the press release.
The overall safety profile of Verzenio remained consistent with previous reports, with all patients having completed or discontinued the two-year treatment course.
Verzenio was the first CDK4/6 inhibitor approved to treat node-positive, high-risk early breast cancer. The drug is currently authorized for use in more than 90 countries worldwide for various breast cancer indications.
Detailed results from the study will be presented at a future medical meeting and submitted for publication in a peer-reviewed journal, according to the company.
Approximately 90% of all breast cancers are detected at an early stage, with about 70% being the hormone receptor-positive, HER2-negative subtype. High-risk patients are three times more likely than those with low-risk characteristics to experience recurrence, with most recurrences developing into incurable metastatic disease. As a prominent player in the pharmaceuticals industry, Eli Lilly’s continued innovation in oncology treatments contributes to its strong market position, which you can analyze in detail through the comprehensive Pro Research Report available on InvestingPro.
The article is based on a press release from Eli Lilly and Company.
In other recent news, Eli Lilly has reported positive results from its Phase 3 ATTAIN-2 trial for the oral GLP-1 drug orforglipron, targeting obesity and type 2 diabetes. The trial demonstrated that participants taking the highest dose of 36 mg lost an average of 22.9 pounds, equating to a 10.5% reduction, compared to a 2.2% reduction with a placebo over 72 weeks. The drug also achieved a 9.6% weight loss and a 1.8% reduction in A1C, with discontinuations at 10.6%. These results have prompted TD Cowen to reiterate a Buy rating for Eli Lilly with a price target of $960, emphasizing the drug’s potential. William Blair also noted that orforglipron exceeded investor expectations, especially in the challenging population of patients with both obesity and type 2 diabetes. Furthermore, BofA Securities maintained its Buy rating on Eli Lilly, citing a projected revenue growth of 35% by 2025, which surpasses the industry average. Eli Lilly plans to pursue global regulatory submissions for orforglipron following these successful trial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.